Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Sold by Massachusetts Financial Services Co. MA

Massachusetts Financial Services Co. MA lessened its position in Organogenesis Holdings Inc. (NASDAQ:ORGOFree Report) by 3.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 269,514 shares of the company’s stock after selling 10,328 shares during the period. Massachusetts Financial Services Co. MA owned approximately 0.21% of Organogenesis worth $857,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ORGO. Swiss National Bank increased its holdings in shares of Organogenesis by 7.9% in the 1st quarter. Swiss National Bank now owns 76,100 shares of the company’s stock worth $580,000 after acquiring an additional 5,600 shares during the period. ProShare Advisors LLC increased its holdings in shares of Organogenesis by 47.6% in the 1st quarter. ProShare Advisors LLC now owns 15,211 shares of the company’s stock worth $117,000 after acquiring an additional 4,905 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Organogenesis by 64.5% in the 1st quarter. JPMorgan Chase & Co. now owns 50,813 shares of the company’s stock worth $387,000 after acquiring an additional 19,932 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Organogenesis by 12.4% in the 1st quarter. Bank of New York Mellon Corp now owns 637,004 shares of the company’s stock worth $4,853,000 after acquiring an additional 70,447 shares during the period. Finally, Bank of Montreal Can increased its holdings in shares of Organogenesis by 8.7% in the 1st quarter. Bank of Montreal Can now owns 21,517 shares of the company’s stock worth $165,000 after acquiring an additional 1,721 shares during the period. Institutional investors and hedge funds own 39.48% of the company’s stock.

Insider Transactions at Organogenesis

In other news, major shareholder Albert Erani sold 197,921 shares of Organogenesis stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $4.37, for a total value of $864,914.77. Following the transaction, the insider now directly owns 59,025,106 shares of the company’s stock, valued at $257,939,713.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 34.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ORGO shares. Cantor Fitzgerald started coverage on shares of Organogenesis in a research note on Wednesday, February 7th. They set an “overweight” rating and a $5.00 target price on the stock. Morgan Stanley lifted their price objective on shares of Organogenesis from $3.00 to $3.50 and gave the stock an “equal weight” rating in a research note on Tuesday, November 14th. Finally, BTIG Research lifted their target price on shares of Organogenesis from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Wednesday, December 27th.

Get Our Latest Stock Report on ORGO

Organogenesis Stock Performance

Organogenesis stock opened at $3.84 on Tuesday. The firm’s 50 day simple moving average is $3.71 and its 200-day simple moving average is $3.05. The company has a market cap of $507.03 million, a P/E ratio of 38.40 and a beta of 1.59. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.77 and a quick ratio of 2.43. Organogenesis Holdings Inc. has a fifty-two week low of $1.79 and a fifty-two week high of $4.70.

Organogenesis Company Profile

(Free Report)

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly, a antimicrobial barrier that enables conformability and fluid drainage.

Featured Stories

Want to see what other hedge funds are holding ORGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organogenesis Holdings Inc. (NASDAQ:ORGOFree Report).

Institutional Ownership by Quarter for Organogenesis (NASDAQ:ORGO)

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.